Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial Of Pembrolizumab And Nintedanib

Next Previous
Trial Profile

Phase Ib Trial Of Pembrolizumab And Nintedanib

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Malignant-mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms PEMBIB

    • Most Recent Events

    • 24 Apr 2023 Planned number of patients changed from 18 to 221.
    • 24 Apr 2023 Planned End Date changed from 1 Jul 2026 to 1 Nov 2028.
    • 24 Apr 2023 Planned primary completion date changed from 1 Jul 2021 to 1 Nov 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top